(Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck (NYSE:MRK) and LaNova Medicines announced Thursday an agreement under which the U.S. pharmaceutical giant is expected ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Speaking to Xinhua, Guenter said China is a country of great importance and enormous potential for the company, and expressed confidence that Merck will invest more in China in the future.

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...

Merck & Co. lowered the top end of its full-year sales forecast after demand for its HPV vaccine fell for a second straight quarter in China. Sales of the Gardasil shot, which is given to ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...